Venus Remedies Ltd

Venus Remedies Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a new all-time high of Rs.872.8 on 2 Feb 2026, underscoring its robust performance and sustained growth trajectory in a competitive market environment.

Venus Remedies Ltd has seen its investment rating downgraded from Strong Buy to Buy as of 1 February 2026, reflecting a recalibration of its valuation and technical outlook despite robust financial performance and quality metrics. The revised Mojo Score now stands at 74.0, signalling a solid but more cautious stance on the stock within the Pharmaceuticals & Biotechnology sector.

Venus Remedies Ltd has recently experienced a notable shift in its valuation parameters, moving from a very attractive to a fair valuation grade. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, invites a closer examination of the company’s price attractiveness relative to its historical performance and peer group within the Pharmaceuticals & Biotechnology sector.

Venus Remedies Ltd surged to hit its upper circuit limit on 30 Jan 2026, propelled by strong buying interest and positive market sentiment. The pharmaceutical company’s shares closed at ₹818.00, marking a 4.67% gain on the day and edging closer to its 52-week high, signalling renewed investor confidence in its growth prospects.

Venus Remedies Ltd., the Chandigarh-based pharmaceutical company specialising in injectable formulations, delivered an impressive Q2 FY26 performance with net profit surging 109.69% quarter-on-quarter to ₹20.13 crores, whilst revenue expanded 40.51% to ₹192.75 crores. The company, commanding a market capitalisation of ₹1,025 crores, saw its shares rally 3.27% to ₹784.90 following the results announcement, extending a remarkable 170.42% gain over the past year.

Venus Remedies Ltd has seen its investment rating upgraded from Buy to Strong Buy, reflecting significant improvements across quality, valuation, financial trends, and technical indicators. The pharmaceutical company’s stellar quarterly performance, combined with bullish technical signals and attractive valuation metrics, has prompted this positive reassessment by MarketsMOJO as of 28 Jan 2026.

Venus Remedies Ltd has demonstrated a significant shift in price momentum and technical indicators, upgrading its outlook from mildly bullish to bullish. With a strong Mojo Score of 80.0 and a recent grade upgrade to Strong Buy, the pharmaceutical and biotechnology company is showing promising signs of sustained upward movement amid a robust market backdrop.

Venus Remedies Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating revised from Strong Buy to Buy as of 20 January 2026. This adjustment reflects nuanced changes across technical indicators, valuation metrics, financial trends, and overall quality assessments, signalling a more cautious but still optimistic outlook for investors.

Venus Remedies Ltd has experienced a notable shift in its technical momentum, transitioning from a bullish to a mildly bullish trend as of late January 2026. Despite a recent downgrade in its Mojo Grade from Strong Buy to Buy, the pharmaceutical company continues to demonstrate resilience with mixed technical indicator signals, reflecting a nuanced market sentiment.

Venus Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed intense selling pressure on 20 Jan 2026, hitting its lower circuit limit and closing at ₹725.0, down 4.67% on the day. The stock’s sharp decline reflects mounting investor concerns amid a three-day losing streak and a notable underperformance relative to its sector and the broader market.

Venus Remedies Ltd has demonstrated a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend, supported by strong weekly and monthly MACD signals and daily moving averages. Despite a slight dip in the stock price on 20 Jan 2026, the overall technical indicators and long-term returns suggest a robust outlook for this Pharmaceuticals & Biotechnology player.

Venus Remedies Ltd has exhibited a nuanced shift in its technical momentum, transitioning from a bullish to a mildly bullish trend, reflecting a complex interplay of indicator signals. Despite some bearish pressures on momentum oscillators, the stock’s overall technical framework remains constructive, supported by strong moving averages and positive MACD readings, suggesting cautious optimism for investors in the Pharmaceuticals & Biotechnology sector.

Venus Remedies Ltd is rated Strong Buy by MarketsMOJO, with this rating last updated on 14 January 2026. While the rating change occurred on that date, the analysis and financial metrics presented here reflect the company’s current position as of 15 January 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Venus Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a significant surge on 14 Jan 2026, hitting its upper circuit limit with a 5.0% gain to close at ₹780.7. This strong buying momentum reflects heightened investor interest amid positive technical and fundamental signals, setting the stock apart from its sector and broader market peers.

Venus Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed intense selling pressure on 12 Jan 2026, culminating in the stock hitting its lower circuit limit. The share price plunged sharply by 4.79%, underperforming both its sector and the broader market, as panic selling and unfilled supply weighed heavily on investor sentiment.